Myeloproliferative neoplasms

Authors

  • Neysimelia Costa Villela Barretos Cancer Hospital
  • Gustavo Zamperlini Hospital Samaritano, São Paulo, SP, Brazil.
  • Patrícia Shimoda Ikeuti Instituto de Oncologia Pediátrica IOP/GRAACC/UNIFESP, São Paulo, SP, Brazil.
  • Roseane Vasconcelos Gouveia Hospital Samaritano, São Paulo, SP, Brazil
  • Simone de Castro Resende Franco Hospital da Criança de Brasília José de Alencar. Brasília, DF, Brazil
  • Luiz Fernando Lopes Barretos Cancer Hospital, Barretos, SP, Brazil.

DOI:

https://doi.org/10.46765/2675-374X.2021v2n4p129

Abstract

 

In addition to the chronic myeloid leukemia (CML) BCR-ABL1+, classic myeloproliferative neoplasms include polycythemia vera, essential thrombocythemia and primary myelofibrosis. These have a very low incidence in the pediatric age group and there is no consensus on treatment in children.

Author Biographies

Neysimelia Costa Villela, Barretos Cancer Hospital

MD. 

Member of the Brazilian Pediatric Myelodysplastic Syndrome Study Group.

Physician at the Pediatric Bone Marrow Transplant Unit, Barretos Cancer Hospital, Barretos, SP, Brazil.

Gustavo Zamperlini, Hospital Samaritano, São Paulo, SP, Brazil.

MD.

Physician at the Pediatric Bone Marrow Transplant Unit, Hospital Samaritano, São Paulo, SP, Brazil. 

Patrícia Shimoda Ikeuti, Instituto de Oncologia Pediátrica IOP/GRAACC/UNIFESP, São Paulo, SP, Brazil.

MD.

Physician at the Pediatric Bone Marrow Transplant Unit, Instituto de Oncologia Pediátrica IOP/GRAACC/UNIFESP, São Paulo, SP, Brazil.  

 

 

 

 

 

Roseane Vasconcelos Gouveia, Hospital Samaritano, São Paulo, SP, Brazil

MD.

Physician at the Pediatric Bone Marrow Transplant Unit, Hospital Samaritano, São Paulo, SP, Brazil. 

Simone de Castro Resende Franco, Hospital da Criança de Brasília José de Alencar. Brasília, DF, Brazil

MD.

Physician at the Pediatric Bone Marrow Transplant Unit, Hospital da Criança de Brasília José de Alencar. Brasília, DF, Brazil.

Luiz Fernando Lopes, Barretos Cancer Hospital, Barretos, SP, Brazil.

MD, PhD.

Chairman of the Brazilian Pediatric Myelodysplastic Syndrome Study Group.

Director of Barretos Chindren´s Cancer Center.

Downloads

Published

11/30/2021

How to Cite

Costa Villela, N., Zamperlini, G. ., Shimoda Ikeuti, P. ., Vasconcelos Gouveia, R., de Castro Resende Franco, S. ., & Lopes, L. F. . (2021). Myeloproliferative neoplasms. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 2(4), 129. https://doi.org/10.46765/2675-374X.2021v2n4p129

Issue

Vol. 2 No. 4 (2021): JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Section

Original article

License

Copyright (c) 2021 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

License and Copyright Policy

The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.

  1. License

    • All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
    • This license permits anyone to:
      • Share: Copy and redistribute the material in any medium or format.
      • Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
    • The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.

    More information about the license can be found here: Creative Commons Attribution 4.0 International License.

  2. Authors’ Rights

    • Authors retain the copyright to their work.
    • Authors grant JBMTCT the right to publish the work and make it openly accessible online.
    • Authors are free to:
      • Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
      • Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.

  3. No Embargo

    • There is no embargo period; articles are made freely available immediately upon publication.

  4. Ethical Use

    • Users of JBMTCT articles must ensure proper citation of the authors and the journal.
    • Articles must not be used in ways that violate ethical or legal standards.

  5. Disclaimer

    • While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.

For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br 

JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.

 

Most read articles by the same author(s)